Galecto, Inc.
General ticker "GLTO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $17.5M (TTM average)
Galecto, Inc. follows the US Stock Market performance with the rate: 40.6%.
Estimated limits based on current volatility of 4.1%: low 22.96$, high 24.94$
Factors to consider:
- Total employees count: 13 (-71.1%) as of 2023
- Top business risk factors: Labor/talent shortage/retention, Operational and conduct risks, Disruption to business operations, Cost savings failure, Inadequate sales and distribution capabilities
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [6.93$, 22.39$]
- 2026-12-31 to 2027-12-31 estimated range: [3.15$, 11.12$]
Financial Metrics affecting the GLTO estimates:
- Negative: with PPE of -2.7 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Negative: Shareholder equity ratio, % of 92.27 > 64.29
- Negative: Investing cash flow per share per price, % of -43.04 <= -14.17
Short-term GLTO quotes
Long-term GLTO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $39.91MM | $22.26MM | $210.87MM |
| Operating Income | $-39.91MM | $-22.26MM | $-210.87MM |
| Non-Operating Income | $1.56MM | $0.86MM | $1.08MM |
| R&D Expense | $23.77MM | $10.79MM | $201.19MM |
| Income(Loss) | $-38.35MM | $-21.40MM | $-209.79MM |
| Taxes | $0.00MM | $0.04MM | $0.05MM |
| Net Income(Loss)* | $-38.35MM | $-21.44MM | $-209.84MM |
| Stockholders Equity | $32.33MM | $15.83MM | $240.38MM |
| Assets | $38.23MM | $17.13MM | $260.53MM |
| Operating Cash Flow | $-36.91MM | $-18.62MM | $-6.73MM |
| Investing Cash Flow | $22.33MM | $11.65MM | $-17.37MM |
| Financing Cash Flow | $2.88MM | $0.32MM | $266.14MM |
| Earnings Per Share** | $-36.08 | $-18.53 | $-143.51 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.